Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

Next Previous
Trial Profile

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; ICT 01 (Primary) ; Pembrolizumab (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Haematological malignancies; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EVICTION
  • Sponsors ImCheck Therapeutics

Most Recent Events

  • 22 May 2025 Results presented in a ImCheck Therapeutics media release.
  • 30 Apr 2025 Results (n=40) reporting preliminary efficacy, safety, pharmacodynamics and dose selection of ICT01 data in the phase 1 portion of this trial presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 23 Apr 2025 According to a ImCheck media release, company will present data from this study in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top